ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

GID Gi Dynamics Inc

0.002
0.00 (0.00%)
25 Apr 2024 - Closed
Delayed by 20 minutes
Share Name Share Symbol Market Type
Gi Dynamics Inc ASX:GID Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.002 0.002 0.003 0.00 01:00:00

GI Dynamics to Provide Shareholder Update on 2017 Second Quarter Results

09/08/2017 11:47pm

Business Wire


Gi Dynamics (ASX:GID)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Gi Dynamics Charts.

GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will update investors on 2017 second quarter results as reported on Form 10Q for the period ended June 30, 2017.

The company will host a webcast at 6 pm EDT 14 August 2017 | 8 am AEST 15 August 2017.

Accessing the Webcast:

The webcast may be accessed by clicking here or on the GI Dynamics website. The link provided will give you access to view and listen to the webcast on a computer, tablet or mobile device.

For those preferring to listen by telephone, please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:

United States (Toll-Free):

        877 407 6184

United Kingdom (Toll-Free):

0 800 756 3429

Germany (Toll-Free):

0 800 182 0040

Australia (Toll-Free):

1 800 687 004

International (Toll; charges will apply):

201 389 0877

The transcript for the call will be available on the company’s website shortly following the webcast.

About GI Dynamics

GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.

GI Dynamics, Inc.Investor RelationsUnited States:Janell Shields, +1 781-357-3280investor@gidynamics.com

1 Year Gi Dynamics Chart

1 Year Gi Dynamics Chart

1 Month Gi Dynamics Chart

1 Month Gi Dynamics Chart

Your Recent History

Delayed Upgrade Clock